Real-world rates and risk factors for subsequent treatment with vertebroplasty or balloon kyphoplasty after initial vertebral augmentation: a retrospective cohort study.

IF 4.2 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM Osteoporosis International Pub Date : 2024-11-23 DOI:10.1007/s00198-024-07294-z
Joshua A Hirsch, Christopher Gilligan, Ronil V Chandra, Allan Brook, Nicolas C Gasquet, Christine N Ricker, Charlotte Wu
{"title":"Real-world rates and risk factors for subsequent treatment with vertebroplasty or balloon kyphoplasty after initial vertebral augmentation: a retrospective cohort study.","authors":"Joshua A Hirsch, Christopher Gilligan, Ronil V Chandra, Allan Brook, Nicolas C Gasquet, Christine N Ricker, Charlotte Wu","doi":"10.1007/s00198-024-07294-z","DOIUrl":null,"url":null,"abstract":"<p><p>The purpose of this study was to determine the real-world incidence and predictors of additional vertebroplasty or balloon kyphoplasty after initial vertebral augmentation, as a proxy for subsequent symptomatic vertebral fracture. Of patients, 15.5% underwent subsequent vertebral augmentation. The patient's comorbidities are strongly associated with risk of subsequent treatment.</p><p><strong>Purpose: </strong>To determine the real-world incidence and predictors of additional vertebroplasty or balloon kyphoplasty after initial vertebral augmentation, as a proxy for subsequent symptomatic and disabling vertebral fracture.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study using commercial insurance claims data (Optum's de-identified Clinformatics® Data Mart Database). Adult patients who underwent subsequent treatment for vertebral fracture within 24 months of initial balloon kyphoplasty (BKP) or vertebroplasty (VP) were classified into \"subsequent treatment\" or \"no subsequent treatment\" cohorts. Survival analysis was applied to investigate the effect of risk factors on subsequent treatment.</p><p><strong>Results: </strong>Between 1 January 2008 and 30 June 2020, a total of 32,513 adult patients underwent a BKP/VP procedure following a diagnosis of vertebral compression fracture in the preceding 12 months. Five thousand thirty-five patients (15.5%) underwent a subsequent BKP/VP treatment within 2 years; 90% had a single fracture level treated. An increased hazard of subsequent treatment was associated with a number of fractures treated at initial BKP/VP (≥ 4 levels, adjusted hazard ratio (AHR) 1.68 (95% CI 1.24-2.26); steroid use, AHR 1.9 (95% CI 1.31-1.48); Elixhauser Comorbidity Index ≥ 4, AHR 1.44 (95% CI 1.17-1.77); and multiple myeloma, AHR 1.31 (95% CI 1.13-1.53)). Age < 70 years was associated with reduced hazard of subsequent treatment (AHR 0.81, 95% CI 0.74-0.89).</p><p><strong>Conclusions: </strong>One in seven patients underwent subsequent treatment for vertebral fracture after initial vertebral augmentation. Baseline patient characteristics were associated with increased risk of subsequent fracture within 2 years, suggesting that a patient's natural history is strongly associated with risk of subsequent treatment rather than the initial surgical procedure itself.</p>","PeriodicalId":19638,"journal":{"name":"Osteoporosis International","volume":" ","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Osteoporosis International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00198-024-07294-z","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

The purpose of this study was to determine the real-world incidence and predictors of additional vertebroplasty or balloon kyphoplasty after initial vertebral augmentation, as a proxy for subsequent symptomatic vertebral fracture. Of patients, 15.5% underwent subsequent vertebral augmentation. The patient's comorbidities are strongly associated with risk of subsequent treatment.

Purpose: To determine the real-world incidence and predictors of additional vertebroplasty or balloon kyphoplasty after initial vertebral augmentation, as a proxy for subsequent symptomatic and disabling vertebral fracture.

Methods: We conducted a retrospective cohort study using commercial insurance claims data (Optum's de-identified Clinformatics® Data Mart Database). Adult patients who underwent subsequent treatment for vertebral fracture within 24 months of initial balloon kyphoplasty (BKP) or vertebroplasty (VP) were classified into "subsequent treatment" or "no subsequent treatment" cohorts. Survival analysis was applied to investigate the effect of risk factors on subsequent treatment.

Results: Between 1 January 2008 and 30 June 2020, a total of 32,513 adult patients underwent a BKP/VP procedure following a diagnosis of vertebral compression fracture in the preceding 12 months. Five thousand thirty-five patients (15.5%) underwent a subsequent BKP/VP treatment within 2 years; 90% had a single fracture level treated. An increased hazard of subsequent treatment was associated with a number of fractures treated at initial BKP/VP (≥ 4 levels, adjusted hazard ratio (AHR) 1.68 (95% CI 1.24-2.26); steroid use, AHR 1.9 (95% CI 1.31-1.48); Elixhauser Comorbidity Index ≥ 4, AHR 1.44 (95% CI 1.17-1.77); and multiple myeloma, AHR 1.31 (95% CI 1.13-1.53)). Age < 70 years was associated with reduced hazard of subsequent treatment (AHR 0.81, 95% CI 0.74-0.89).

Conclusions: One in seven patients underwent subsequent treatment for vertebral fracture after initial vertebral augmentation. Baseline patient characteristics were associated with increased risk of subsequent fracture within 2 years, suggesting that a patient's natural history is strongly associated with risk of subsequent treatment rather than the initial surgical procedure itself.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
初次椎体增强术后接受椎体成形术或球囊椎体后凸成形术治疗的实际比率和风险因素:一项回顾性队列研究。
本研究旨在确定初次椎体增强术后追加椎体成形术或球囊椎体后凸成形术的实际发生率和预测因素,以此作为后续症状性椎体骨折的替代指标。15.5%的患者接受了后续椎体增强术。目的:确定初次椎体增强术后追加椎体成形术或球囊后凸成形术的实际发生率和预测因素,作为后续症状性和致残性椎体骨折的替代指标:我们利用商业保险理赔数据(Optum 的去标识化 Clinformatics® Data Mart 数据库)进行了一项回顾性队列研究。我们将初次接受球囊椎体成形术(BKP)或椎体成形术(VP)后 24 个月内接受椎体骨折后续治疗的成年患者分为 "后续治疗 "队列和 "无后续治疗 "队列。采用生存分析法研究风险因素对后续治疗的影响:2008年1月1日至2020年6月30日期间,共有32513名成年患者在前12个月诊断出椎体压缩性骨折后接受了BKP/VP手术。有 535 名患者(15.5%)在 2 年内接受了后续 BKP/VP 治疗,其中 90% 接受了单层骨折治疗。后续治疗的风险增加与初始 BKP/VP 治疗的骨折数量有关(≥ 4 级,调整风险比 (AHR) 1.68 (95% CI 1.24-2.26);使用类固醇,AHR 1.9 (95% CI 1.31-1.48);Elixhauser 合并症指数≥ 4,AHR 1.44 (95% CI 1.17-1.77);多发性骨髓瘤,AHR 1.31 (95% CI 1.13-1.53))。年龄结论:每七名患者中就有一人在初次椎体增强术后因椎体骨折接受了后续治疗。患者的基线特征与两年内发生后续骨折的风险增加有关,这表明患者的自然病史与后续治疗的风险密切相关,而非初始手术本身。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Osteoporosis International
Osteoporosis International 医学-内分泌学与代谢
CiteScore
8.10
自引率
10.00%
发文量
224
审稿时长
3 months
期刊介绍: An international multi-disciplinary journal which is a joint initiative between the International Osteoporosis Foundation and the National Osteoporosis Foundation of the USA, Osteoporosis International provides a forum for the communication and exchange of current ideas concerning the diagnosis, prevention, treatment and management of osteoporosis and other metabolic bone diseases. It publishes: original papers - reporting progress and results in all areas of osteoporosis and its related fields; review articles - reflecting the present state of knowledge in special areas of summarizing limited themes in which discussion has led to clearly defined conclusions; educational articles - giving information on the progress of a topic of particular interest; case reports - of uncommon or interesting presentations of the condition. While focusing on clinical research, the Journal will also accept submissions on more basic aspects of research, where they are considered by the editors to be relevant to the human disease spectrum.
期刊最新文献
Correction: Exposure to air pollution might decrease bone mineral density and increase the prevalence of osteoporosis: A mendelian randomization study. Type 2 diabetes incidence in patients initiating denosumab or alendronate treatment: a primary care cohort study. Real-world efficacy of a teriparatide biosimilar (RGB-10) compared with reference teriparatide on bone mineral density, trabecular bone score, and bone parameters assessed using quantitative ultrasound, 3D-SHAPER® and high-resolution peripheral computer tomography in postmenopausal women with osteoporosis and very high fracture risk. One versus 2 years of alendronate following denosumab: the CARD extension. Association of proton-density fat fraction with osteoporosis: a systematic review and meta-analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1